KRAS and thyroid cancer, nonmedullary, 2: Despite the highly sensitive technique being used in our study, circulating BRAF, NRAS, and TERT promoter mutation alleles were not detected in the plasma of patients with PTC and FTC, with the exception of one KRAS mutation in the patient with indeterminate lesion.